Keymed Biosciences Inc.
2162
Rang in aandelen
#4889
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China... Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
Aandeelprijs
$10.08
Marktkapitalisatie
$2.97B
Verandering (1 dag)
-8.18%
Verandering (1 jaar)
25.74%
Land
CN
Handel Keymed Biosciences Inc. (2162)
Categorie
Healthcare
P/B-ratio voor Keymed Biosciences Inc. (2162)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Keymed Biosciences Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Keymed Biosciences Inc. van 2019 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2025 | 4.74 | 54.27% |
| 2024 | 3.07 | -21.10% |
| 2023 | 3.89 | 10.61% |
| 2022 | 3.52 | 186.05% |
| 2021 | 1.23 | -110.90% |
| 2020 | -11.29 | -81.08% |
| 2019 | -59.65 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| 6.1824 | - |
NL
|
|
| - | - |
CH
|
